Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

08 déc. 2014 13h30 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Announces Presentation of Positive Updated Results from Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS at ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of updated results from an ongoing Phase 1b/2 University of...
07 déc. 2014 12h30 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Announces Presentation of Results From Phase 3 VALOR Trial at ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 7, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that results from the Company's Phase 3 VALOR trial of vosaroxin and...
02 déc. 2014 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals to Host Conference Call and Slide Webcast Tuesday, December 9 Following Presentation of Phase 3 VALOR Trial Results at ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call and slide webcast on Tuesday, December 9,...
24 nov. 2014 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Announces Publication of REVEAL-1 Trial Results in the British Journal of Haematology

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of results from the Company's REVEAL-1 (Response Evaluation...
19 nov. 2014 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Announces Publication of Vosaroxin Phase 1b/2 AML Trial Results in Haematologica

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the online publication of results from the Company's Phase 1b/2 study of...
17 nov. 2014 09h05 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Announces Late-Breaking Presentation of Phase 3 VALOR Trial at ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that results from the Company's Phase 3 VALOR trial of vosaroxin and...
10 nov. 2014 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights

Announces Submission of Letter of Intent to File MAA for Vosaroxin in Relapsed or Refractory AML With the European Medicines Agency Announces Upcoming Presentations at ASH Annual Meeting,...
05 nov. 2014 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer and President of Sunesis, will...
03 nov. 2014 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis to Host Conference Call on November 10th to Discuss Third Quarter 2014 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced it will host a conference call on Monday, November 10, 2014 at 10:30 am...
06 oct. 2014 06h30 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia

Trial Does Not Reach Primary Endpoint of Statistically Significant Improvement in Overall Survival Shows Significant Survival Benefit when Censored for Transplant Safety Profile Consistent...

Page précédente